Meridian Bioscience (VIVO) Getting Somewhat Favorable News Coverage, Analysis Shows

Meridian Bioscience (VIVO) Getting Somewhat Favorable News Coverage, Analysis Shows

News articles about Meridian Bioscience (NASDAQ:VIVO) have trended somewhat positive recently, according to AlphaOne Sentiment Analysis. AlphaOne, a unit of Accern, identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Meridian Bioscience earned a news impact score of 0.22 on AlphaOne’s scale. AlphaOne also assigned media headlines about the company an impact score of 40 out of 100, indicating that recent news coverage is unlikely to have an impact on the stock’s share price in the near term.

These are some of the media headlines that may have impacted AlphaOne Sentiment Analysis’s scoring:

Shares of Meridian Bioscience (NASDAQ:VIVO) traded up 1.09% on Thursday, hitting $13.95. 24,633 shares of the stock were exchanged. The stock has a market cap of $588.72 million, a PE ratio of 19.68 and a beta of 1.00. The company’s 50 day moving average is $14.16 and its 200-day moving average is $14.86. Meridian Bioscience has a 52-week low of $10.75 and a 52-week high of $20.68.

Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings results on Friday, April 28th. The company reported $0.22 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.19 by $0.03. The company had revenue of $54.13 million for the quarter, compared to analyst estimates of $51.16 million. Meridian Bioscience had a net margin of 15.13% and a return on equity of 18.51%. The firm’s revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.24 earnings per share. Analysts predict that Meridian Bioscience will post $0.68 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, May 18th. Shareholders of record on Monday, May 8th were paid a $0.125 dividend. The ex-dividend date of this dividend was Thursday, May 4th. This represents a $0.50 annualized dividend and a yield of 3.62%. Meridian Bioscience’s dividend payout ratio is currently 71.43%.

Several equities research analysts have recently commented on VIVO shares. CL King started coverage on shares of Meridian Bioscience in a report on Tuesday, March 28th. They issued a “neutral” rating for the company. Canaccord Genuity boosted their price target on shares of Meridian Bioscience from $13.00 to $15.00 and gave the company a “hold” rating in a report on Wednesday, May 3rd. Finally, Zacks Investment Research upgraded shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a report on Saturday, April 29th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $14.75.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:VIVO”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment